CLAU Test Results (CLinical Assessment And Endothelin fUnction Assessment After Endothelin Receptor Antagonist) : Randomized Controlled Clinical Trial of Bosentan for Intermittent Claudication in Peripheral Arterial Disease

Trial Profile

CLAU Test Results (CLinical Assessment And Endothelin fUnction Assessment After Endothelin Receptor Antagonist) : Randomized Controlled Clinical Trial of Bosentan for Intermittent Claudication in Peripheral Arterial Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Dec 2015

At a glance

  • Drugs Bosentan (Primary)
  • Indications Intermittent claudication; Peripheral arterial disorders
  • Focus Proof of concept; Therapeutic Use
  • Acronyms CLAU
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Dec 2015 New trial record
    • 06 Nov 2015 Primary endpoint of change in flow-mediated arterial dilation (FMAD) respect baseline values has been met, according to results published in the American Journal of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top